News Release

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Management will also participate in two upcoming investor healthcare conferences

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2024.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please dial (888) 596-4144 or (646) 968-2525 and refer to conference ID 6257274. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. 

Q4 Investor Conferences
Management will also be participating in the following investor healthcare conferences:

  • The Guggenheim Inaugural Global Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Wednesday, November 13, 2024 at 3:30 pm ET.
  • The 6th Annual Wolfe Research Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, on Wednesday, November 20, 2024 at 3:20 pm ET.

Live and archived webcasts of all presentations can be viewed at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Glenn Farrell 
(385) 318-3718 
PR@myriad.com